Intertek opens new drug stability testing facility citing demand and bigger med devices

By Gareth Macdonald contact

- Last updated on GMT

New Intertek site opens in UK: event attended by staff and a very tall photographer
New Intertek site opens in UK: event attended by staff and a very tall photographer
Intertek has opened a new stability facility citing demand for bespoke drug and device services like abuse potential assessments and stress testing.

The facility in Royston near Cambridge, UK houses capacity for stability testing for small molecule and biopharmaceutical drugs and medical devices. The site will operate as part of Intertek’s network, which includes sites in Manchester, New Jersey in the US and Melbourne, Australia.

Intertek told us “The drive for the new GMP stability facility is primarily client demand for both stability storage and stability programs that include testing​” adding that it will provide capacity for bespoke tests like risk management and use/misuse studies.  

The firm added that “The sheer volume of the new expansion allows us to store bulkier or larger products such as some medical devices. These can take up a lot or room in a stability chamber.”

Stability history

The Cambridge site – which Intertek acquired along with Melbourn in 2013​ – has provided stability testing services to the pharmaceutical and medical devices sectors for more than 20 years for drugs for a range of conditions according to Intertek.

Our expertise for drug stability includes areas of specialism such as inhaled products behind treatments for Asthma, Cystic Fibrosis, Diabetes, and Chronic Obstructive Pulmonary disease and biologics such as monoclonal antibodies, proteins and antibody drug conjugates​.”

 In addition to regulated pharmaceuticals and biologics, the new stability site will also house testing services for ‘nutraceuticals,’ which include things like vitamins, nutritional supplements, herbal remedies and so called functional foods.

The firm told us that demand for such products was also a factor, explaining that “There is also a demand for stability testing for nutraceuticals and functional foods and the increased capacity will allow a much wider service provision than before.​”

Related news

Show more

Related products

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers